• Safety [ Designated as safety issue: Yes ]
  
• Survival and immune function of TGFβ-resistant LMP-specific cytotoxic T-lymphocyte lines [ Designated as safety issue: No ]
  
• Anti-viral and anti-tumor effects [ Designated as safety issue: No ]
  
• Safety and response to extended dosage regimen [ Designated as safety issue: Yes ]
  

OBJECTIVES:

• To determine the safety of 2 intravenous injections of autologous or allogeneic TGFβ-resistant LMP-specific cytotoxic T-lymphocytes (CTL) in patients with relapsed Hodgkin or non-Hodgkin lymphoma.
• To determine the survival and the immune function of TGFβ-resistant LMP-specific cytotoxic T-lymphocyte lines.
• To assess the anti-viral and anti-tumor effects of TGFβ-resistant LMP-specific CTL.
• To obtain preliminary information on the safety and response to an extended dosage regimen.

OUTLINE: Peripheral blood are collected from the patient or donor for generation of TGFβ-resistant LMP-specific cytotoxic T lymphocytes (CTLs).

Patients receive TGFβ-resistant LMP-specific CTLs over 1-10 minutes on days 0 and 14.

After completion of study treatment, patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for up to 10 years.

DISEASE CHARACTERISTICS:

• Diagnosis of any of the following:

  • Epstein-Barr Virus (EBV)-positive lymphoma
  • EBV (associated)-T/NK-lymphoproliferative disease
  • Lymphoepithelioma regardless of the histological subtype
• In second or subsequent relapse, including after autologous or syngeneic stem cell transplantation (SCT) OR patients with detectable/relapsed disease after allogeneic SCT
• Diagnosis confirmed on a relapse biopsy sample
• Tumor tissue EBV positive
• If post allogeneic SCT, must have ≥ 50% donor chimerism in either peripheral blood or bone marrow
• No evidence of GVHD > grade II at time of enrollment

PATIENT CHARACTERISTICS:

• Karnofsky performance status 50-100%
• Life expectancy ≥ 6 weeks
• No severe intercurrent infection
• HIV negative at time of procurement cells for cytotoxic T lymphocytes (CTL) generation
• Bilirubin ≤ 3 times normal
• AST≤ 5 times normal
• Hemoglobin > 8.0 g/dL
• Creatinine ≤ 2 times normal for age
• Oxygen saturations > 93% on room air (measured by pulse oximetry)
• Not pregnant or nursing
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• More than 1 month since prior investigational agent